Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Recommendation of “Hold” from Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have earned an average recommendation of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $8.24.

A number of equities analysts have weighed in on ZNTL shares. Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wells Fargo & Company dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $1.25 on Friday. The firm has a market cap of $89.94 million, a PE ratio of -0.50 and a beta of 1.81. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $13.00. The company’s 50-day moving average price is $1.33 and its two-hundred day moving average price is $2.19.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, meeting analysts’ consensus estimates of ($0.67). On average, research analysts expect that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers purchased 21,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The stock was acquired at an average cost of $1.40 per share, with a total value of $29,400.00. Following the completion of the purchase, the director now directly owns 281,192 shares in the company, valued at approximately $393,668.80. This represents a 8.07% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Corton Capital Inc. bought a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth approximately $32,000. Captrust Financial Advisors acquired a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $33,000. Cerity Partners LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 58.7% in the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock valued at $33,000 after buying an additional 7,579 shares during the period. Prudential Financial Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $39,000. Finally, Vident Advisory LLC acquired a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $45,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.